It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We identify biomarkers for disease progression in three type 2 diabetes cohorts encompassing 2,973 individuals across three molecular classes, metabolites, lipids and proteins. Homocitrulline, isoleucine and 2-aminoadipic acid, eight triacylglycerol species, and lowered sphingomyelin 42:2;2 levels are predictive of faster progression towards insulin requirement. Of ~1,300 proteins examined in two cohorts, levels of GDF15/MIC-1, IL-18Ra, CRELD1, NogoR, FAS, and ENPP7 are associated with faster progression, whilst SMAC/DIABLO, SPOCK1 and HEMK2 predict lower progression rates. In an external replication, proteins and lipids are associated with diabetes incidence and prevalence. NogoR/RTN4R injection improved glucose tolerance in high fat-fed male mice but impaired it in male db/db mice. High NogoR levels led to islet cell apoptosis, and IL-18R antagonised inflammatory IL-18 signalling towards nuclear factor kappa-B in vitro. This comprehensive, multi-disciplinary approach thus identifies biomarkers with potential prognostic utility, provides evidence for possible disease mechanisms, and identifies potential therapeutic avenues to slow diabetes progression.
There is an urgent need for biomarkers for type 2 diabetes progression that provide a deeper understanding of the disease process. Here, the authors identify biomarkers in three molecular classes, replicate them in other cohorts and explore top protein biomarkers in detail in functional studies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Donnelly, Louise A. 2 ; Akalestou, Elina 3 ; Lopez-Noriega, Livia 3 ; Melhem, Rana 4 ; Güneş, Ayşim 5 ; Abou Azar, Frederic 4 ; Efanov, Alexander 6 ; Georgiadou, Eleni 3
; Muniangi-Muhitu, Hermine 3 ; Sheikh, Mahsa 3 ; Giordano, Giuseppe N. 7
; Åkerlund, Mikael 7 ; Ahlqvist, Emma 7
; Ali, Ashfaq 8
; Banasik, Karina 9
; Brunak, Søren 9
; Barovic, Marko 10 ; Bouland, Gerard A. 11
; Burdet, Frédéric 12 ; Canouil, Mickaël 13
; Dragan, Iulian 12 ; Elders, Petra J. M. 14 ; Fernandez, Celine 7
; Festa, Andreas 15 ; Fitipaldi, Hugo 7
; Froguel, Phillippe 16
; Gudmundsdottir, Valborg 17
; Gudnason, Vilmundur 17
; Gerl, Mathias J. 18
; van der Heijden, Amber A. 14 ; Jennings, Lori L. 19
; Hansen, Michael K. 20
; Kim, Min 21 ; Leclerc, Isabelle 22 ; Klose, Christian 23 ; Kuznetsov, Dmitry 12 ; Mansour Aly, Dina 7 ; Mehl, Florence 12
; Marek, Diana 12 ; Melander, Olle 7 ; Niknejad, Anne 12 ; Ottosson, Filip 24
; Pavo, Imre 25 ; Duffin, Kevin 6 ; Syed, Samreen K. 6 ; Shaw, Janice L. 6 ; Cabrera, Over 6 ; Pullen, Timothy J. 26
; Simons, Kai 27 ; Solimena, Michele 28 ; Suvitaival, Tommi 8 ; Wretlind, Asger 8
; Rossing, Peter 29
; Lyssenko, Valeriya 30 ; Legido Quigley, Cristina 21 ; Groop, Leif 31
; Thorens, Bernard 32
; Franks, Paul W. 33
; Lim, Gareth E. 4 ; Estall, Jennifer 5
; Ibberson, Mark 12
; Beulens, Joline W. J. 34
; ’t Hart, Leen M 35
; Pearson, Ewan R. 2
; Rutter, Guy A. 36
1 Amsterdam Public Health Institute, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location VUMC, Department of Epidemiology and Data Science, Amsterdam, the Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
2 University of Dundee, Population Health & Genomics, School of Medicine, Dundee, UK (GRID:grid.8241.f) (ISNI:0000 0004 0397 2876)
3 Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, Section of Cell Biology and Functional Genomics, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
4 CHUM Research Centre and University of Montreal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
5 IRCM and University of Montreal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
6 Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, US (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544)
7 Lund University, Department of Clinical Sciences, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
8 Steno Diabetes Center Copenhagen, Gentofte, Denmark (GRID:grid.419658.7) (ISNI:0000 0004 0646 7285)
9 Novo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
10 Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany (GRID:grid.507329.a)
11 Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
12 Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland (GRID:grid.419765.8) (ISNI:0000 0001 2223 3006)
13 Lille University Hospital, INSERM U1283, CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, University of Lille, Lille, France (GRID:grid.410463.4) (ISNI:0000 0004 0471 8845)
14 Amsterdam Public Health Research Institute, Amsterdam UMC–location VUmc, Department of General Practice and Elderly Care Medicine, Amsterdam, the Netherlands (GRID:grid.16872.3a) (ISNI:0000 0004 0435 165X)
15 Eli Lilly Regional Operations GmbH, Vienna, Austria (GRID:grid.4514.4); LK Stockerau, 1st Medical Department, Niederösterreich, Austria (GRID:grid.4514.4)
16 Lille University Hospital, INSERM U1283, CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, University of Lille, Lille, France (GRID:grid.410463.4) (ISNI:0000 0004 0471 8845); Endocrinology and Metabolism, Imperial College London, Division of Systems Biology, Department of Diabetes, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
17 University of Iceland, Faculty of Medicine, Reykjavik, Iceland (GRID:grid.14013.37) (ISNI:0000 0004 0640 0021); Icelandic Heart Association, Kopavogur, Iceland (GRID:grid.420802.c) (ISNI:0000 0000 9458 5898)
18 Lipotype GmbH, Dresden, Germany (GRID:grid.420802.c)
19 Novartis Institutes for Biomedical Research, Cambridge, USA (GRID:grid.418424.f) (ISNI:0000 0004 0439 2056)
20 Janssen Research & Development, Cardiovascular and Metabolic Disease Research, Spring House, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927)
21 Steno Diabetes Center Copenhagen, Gentofte, Denmark (GRID:grid.419658.7) (ISNI:0000 0004 0646 7285); Faculty of Life Sciences and Medicines, King’s College London, Institute of Pharmaceutical Science, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
22 Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, Section of Cell Biology and Functional Genomics, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); CHUM Research Centre and University of Montreal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
23 Lipotype GmbH, Dresden, Germany (GRID:grid.14848.31)
24 Lund University, Department of Clinical Sciences, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Statens Serum Institut, Section for Clinical Mass Spectrometry, Danish Center for Neonatal Screening, Department of Congenital Disorders, Copenhagen, Denmark (GRID:grid.6203.7) (ISNI:0000 0004 0417 4147)
25 Eli Lilly Regional Operations GmbH, Vienna, Austria (GRID:grid.6203.7)
26 Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, Section of Cell Biology and Functional Genomics, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Guy’s Campus King’s College London, Department of Diabetes, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
27 Lipotype GmbH, Dresden, Germany (GRID:grid.13097.3c)
28 Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany (GRID:grid.507329.a); University Hospital and Medical Faculty Carl Gustav Carus, Molecular Diabetology, TU Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
29 Steno Diabetes Center Copenhagen, Gentofte, Denmark (GRID:grid.419658.7) (ISNI:0000 0004 0646 7285); University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
30 University of Bergen, Department of Clinical Science, Center for Diabetes Research, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443); Lund University Diabetes Centre, Skåne University Hospital, Genomics, Diabetes and Endocrinology Unit, Department of Clinical Sciences Malmö, Malmö, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987)
31 Lund University, Department of Clinical Sciences, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Helsinki University, Finnish Institute of Molecular Medicine, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
32 University of Lausanne, Center for Integrative Genomics, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204)
33 Lund University, Department of Clinical Sciences, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Harvard School of Public Health, Department of Nutrition, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
34 Amsterdam Public Health Institute, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location VUMC, Department of Epidemiology and Data Science, Amsterdam, the Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
35 Amsterdam Public Health Institute, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location VUMC, Department of Epidemiology and Data Science, Amsterdam, the Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978); Leiden University Medical Center, Department of Biomedical Data Sciences, Section Molecular Epidemiology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
36 Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, Section of Cell Biology and Functional Genomics, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); CHUM Research Centre and University of Montreal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore (GRID:grid.59025.3b) (ISNI:0000 0001 2224 0361)




